NCT06125080

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: Huihua Xiong · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).

Conditions

• TNBC - Triple-Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Utidelone	Utidelone (30 mg/m2, days 1-5, every 3 weeks)
DRUG	Tirelizumab	Tirelizumab（200mg, day1, every 3 weeks）
DRUG	Bevacizumab	Bevacizumab(7.5mg/kg, day1, every 3 weeks)

Timeline

• Start date: 2023-10-30
• Primary completion: 2025-10-30
• Completion: 2026-10-30
• First posted: 2023-11-09
• Last updated: 2023-11-09

Locations

1 site across 1 country: China